Your browser doesn't support this page

This website uses the latest technology, and it looks like your browser doesn't support some of the latest features.

You'll probably be able to see the content with the browser you have, but we encourage you to choose a browser with better support for the future of the web. These support all the features used (and they're free too):

Google Chrome Mozilla Firefox Safari Dismiss
Manohar Pradhan

Contact information

Please contact Manohar Pradhan for more information

Endometrial Cancer

DNA Ploidy and Nucleotyping

We have analyzed DNA ploidy distribution in about 1.000 samples from patients with endometrial cancer. The project is in collaboration with clinicians from Haukeland University Hospital. The results show that DNA ploidy identifies patients with a high risk of recurrence and metastasis to lymph nodes.

The chromatin organization was analyzed using Nucleotyping, showing that Nucleotyping is an independent prognostic marker for cancer-related death, and stronger than DNA ploidy. An advantage in this project is that the samples were collected prior to surgery and can be used for adjustment of the treatment plan for each individual patient.

Ref: Njølstad TS et al.,DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer. Br J Cancer. May 2015

Serous Adenocarcinoma

Serous adenocarcinoma is a relatively rare but aggressive endometrial malignancy. In order to establish a prognostic marker, we performed DNA ploidy analyses and assessed the expression of several cancer-related genes through immunohistochemistry: p53, estrogen receptor, progesterone receptor and Ki-67 in 73 patient samples. One of our DNA ploidy parameters stood out as a potential marker: 5c ER correlates to relapse, progression-free survival and total survival ( 5cER counts the number of nuclei with a DNA content higher than 5c, i.e. corresponding to more than 2,5 times the normal chromosome number).

Ref: Pradhan M et al., DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium. Virchows Arch. 2012 Sep;461(3):291-8.

Endometrioid Adenocarcinoma

Endometrioid adenocarcinoma of the uterus is a less aggressive cancer type. We have evaluated the prognostic significance of DNA ploidy in 937 patients with stage I and II endometrioid adenocarcinoma. The results show that patients with aneuploid tumors were less likely to have progression-free survival, confirming that DNA ploidy is a prognostic marker for this disease.

Ref: Pradhan M et al., Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium. Annals of Oncology. 2012 May;23(5):1178-84.

Related articles

Chief Editor: Prof. Håvard E. Danielsen
Copyright Oslo University Hospital. Visiting address: The Norwegian Radium Hospital, Ullernchausséen 64, Oslo. Tel: 22 78 23 20